OPTR Related Upgrades
-
BofA/Merrill Lynch Upgrades Optimer Pharma (OPTR) to Buy
-
Baird Upgrades Optimer Pharmaceuticals (OPTR) to Outperform; Catalyst Flow
-
JMP Securities Upgrades Optimer Pharmaceuticals (OPTR) to Market Outperform, Price Target $16
-
Ladenburg Thalmann Upgrades Optimer Pharmaceuticals (OPTR) to Buy
-
Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
-
Needham Upgrades Optimer Pharmaceuticals (OPTR) to Buy
Back to OPTR Stock Lookup
